[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP4164626A4 - Combination antibacterial composition and method for antibacterial therapy - Google Patents

Combination antibacterial composition and method for antibacterial therapy

Info

Publication number
EP4164626A4
EP4164626A4 EP21825333.4A EP21825333A EP4164626A4 EP 4164626 A4 EP4164626 A4 EP 4164626A4 EP 21825333 A EP21825333 A EP 21825333A EP 4164626 A4 EP4164626 A4 EP 4164626A4
Authority
EP
European Patent Office
Prior art keywords
antibacterial
combination
therapy
composition
antibacterial composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21825333.4A
Other languages
German (de)
French (fr)
Other versions
EP4164626A1 (en
Inventor
Rajneesh Taneja
Pratik Shivram Mahajan
Srinivas Panguluri
Chayapathy Issa
Pradip Ghosh
Santanu Chakraborty
Amit Antarkar
Abhijit Deshmukh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Global Alliance for TB Drug Development Inc
Original Assignee
Mylan Laboratories Ltd
Global Alliance for TB Drug Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd, Global Alliance for TB Drug Development Inc filed Critical Mylan Laboratories Ltd
Publication of EP4164626A1 publication Critical patent/EP4164626A1/en
Publication of EP4164626A4 publication Critical patent/EP4164626A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP21825333.4A 2020-06-15 2021-06-14 Combination antibacterial composition and method for antibacterial therapy Pending EP4164626A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041025097 2020-06-15
PCT/US2021/037245 WO2021257461A1 (en) 2020-06-15 2021-06-14 Combination antibacterial composition and method for antibacterial therapy

Publications (2)

Publication Number Publication Date
EP4164626A1 EP4164626A1 (en) 2023-04-19
EP4164626A4 true EP4164626A4 (en) 2024-07-03

Family

ID=79268317

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21825333.4A Pending EP4164626A4 (en) 2020-06-15 2021-06-14 Combination antibacterial composition and method for antibacterial therapy

Country Status (2)

Country Link
EP (1) EP4164626A4 (en)
WO (1) WO2021257461A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020998A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
US20110190199A1 (en) * 2008-09-03 2011-08-04 Pfizer Inc. Combination Therapy for Tuberculosis
WO2016120258A1 (en) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Dispersible compositions
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
WO2021016012A1 (en) * 2019-07-19 2021-01-28 The Global Alliance For Tb Drug Development, Inc. Pretomanid compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (en) * 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
WO2014016850A1 (en) * 2012-07-24 2014-01-30 Mylan Laboratories Limited Stable pharmaceutical composition of fluindione
WO2016116892A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020998A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
US20110190199A1 (en) * 2008-09-03 2011-08-04 Pfizer Inc. Combination Therapy for Tuberculosis
WO2016120258A1 (en) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Dispersible compositions
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
WO2021016012A1 (en) * 2019-07-19 2021-01-28 The Global Alliance For Tb Drug Development, Inc. Pretomanid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021257461A1 *

Also Published As

Publication number Publication date
WO2021257461A1 (en) 2021-12-23
EP4164626A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
IL279748A (en) Composition and method for treating pain
IL285886A (en) Compositions and methods for treating laminopathies
GB202011871D0 (en) Composition and method
IL277315B (en) Methods and composition for treating coronavirus infection
IL285796A (en) Methods and compositions for treating
EP4181928A4 (en) Compositions and methods for treating lung inflammation
GB202100998D0 (en) Composition and method
GB202100997D0 (en) Composition and method
GB2593010B (en) Composition and Method
EP4164626A4 (en) Combination antibacterial composition and method for antibacterial therapy
EP4164645A4 (en) Combination antibacterial composition and method for antibacterial therapy
GB202102310D0 (en) Composition and method
GB202016644D0 (en) Composition and method
EP3946302A4 (en) Methods and compositions for treating pain
GB2603642B (en) Method and composition
EP4142687C0 (en) Composition for treating and/or preventing vestibulodynia
EP4175627A4 (en) Composition and method for treating infections
GB2598715B (en) Composition and method
EP4069701A4 (en) Composition and method for treating cancer
GB202218059D0 (en) Treatment composition
GB202113085D0 (en) Composition and method
GB202113086D0 (en) Composition and method
GB202109827D0 (en) Method and composition
GB202108601D0 (en) Composition and method
GB202105673D0 (en) Method and composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240603

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20240528BHEP

Ipc: A61P 17/02 20060101ALI20240528BHEP

Ipc: A61K 31/7036 20060101ALI20240528BHEP

Ipc: A61K 31/20 20060101AFI20240528BHEP